CTT is a pre-revenue development-stage company that develops thin-film strips that dissolve on contact with saliva to deliver active ingredients without water. The company focuses on nicotine strips for smoking cessation and vitamin strips as nutritional supplements. CTT plans to sell these products through direct retail and international licensing or distribution agreements. The company commercializes patented technology that uses a specific heating-and-cooling gel process to ensure precise dosing. CTT currently lacks manufacturing facilities and commercial production in the U.S., relying instead on its patent portfolio as its primary asset. The company plans to acquire equipment and establish a facility in Florida to begin in-house production. For complex pharmaceutical applications, CTT expects to partner with larger firms to manage high capital requirements. CTT prioritizes launching vitamin strips, which avoid FDA approval requirements, before pursuing regulatory paths for nicotine products. CTT holds patents in the U.S., Canada, Europe, and Mexico, and its path to commercialization depends on its ability to raise capital and achieve regulatory approvals for its nicotine-based products.